CBD brand Elixinol has acquired the intellectual property rights over microencapsulated technology developed by Bionova. This transaction will allow Elixinol to utilize the technology globally. In addition, Bionova will be the exclusive manufacturer and supplier within the European Union of Elixinol products developed using the microencapsulated technology.

“By extending the useful life of cannabinoids and delivering them more efficiently in the human body, we can improve the health and well-being of many people,” said Bionova’s Jamie Fabregas Casal PhD, the inventor of the microencapsulation technology. “It is exciting to have Elixinol leverage the technology on a global scale.”

Consideration for the intellectual property rights are as follows:

Bionova to be the exclusive manufacturer and supplier of Elixinol products developed by using the microencapsulated technology within the European Union based on minimum volumes of supply for the period established by law for any of the intellectual property rights related to the microencapsulation technology; and

An annual fixed amount of €25,000 for each non-European Union country in which Elixinol exploits the microencapsulated technology until patent rights over the microencapsulated technology have been granted in that country, increasing to €50,000 annually once patent rights are granted.